BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Belousova V, Abd-Rabou AA, Mousa SA. Recent advances and future directions in the management of hepatitis C infections. Pharmacol Ther 2015;145:92-102. [PMID: 25200121 DOI: 10.1016/j.pharmthera.2014.09.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Abd-Rabou AA, Bharali DJ, Mousa SA. Viramidine-Loaded Galactosylated Nanoparticles Induce Hepatic Cancer Cell Apoptosis and Inhibit Angiogenesis. Appl Biochem Biotechnol 2020;190:305-24. [PMID: 31346920 DOI: 10.1007/s12010-019-03090-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 He S, Jain P, Lin B, Ferrer M, Hu Z, Southall N, Hu X, Zheng W, Neuenswander B, Cho CH, Chen Y, Worlikar SA, Aubé J, Larock RC, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ. High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. ACS Comb Sci 2015;17:641-52. [PMID: 26332742 DOI: 10.1021/acscombsci.5b00101] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
3 Dean CE. Social inequality, scientific inequality, and the future of mental illness. Philos Ethics Humanit Med 2017;12:10. [PMID: 29258528 DOI: 10.1186/s13010-017-0052-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
4 Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
5 Buchanan R, Nash KL. Hepatitis C. Medicine 2015;43:607-12. [DOI: 10.1016/j.mpmed.2015.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Nawtaisong P, Fraser ME, Carter JR, Fraser MJ Jr. Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells. Virology 2015;481:223-34. [PMID: 25840398 DOI: 10.1016/j.virol.2015.02.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
7 Pecoraro V, Cariani E, Villa E, Trenti T. Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review. Eur J Clin Invest 2016;46:737-48. [PMID: 27376688 DOI: 10.1111/eci.12656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Venkatesan A, Prabhu Dass J F. Review on chemogenomic approaches towards hepatitis C viral targets. J Cell Biochem 2019;120:12167-81. [PMID: 30887580 DOI: 10.1002/jcb.28581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 Tamborini Permunian E, Gervaso L, Gerdes V, Moja L, Guasti L, Squizzato A. Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review. Intern Emerg Med 2018;13:775-90. [PMID: 29611106 DOI: 10.1007/s11739-018-1828-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Balasco N, Barone D, Iaccarino E, Sandomenico A, De Simone A, Ruvo M, Vitagliano L. Intrinsic structural versatility of the highly conserved 412-423 epitope of the Hepatitis C Virus E2 protein. Int J Biol Macromol 2018;116:620-32. [PMID: 29758309 DOI: 10.1016/j.ijbiomac.2018.05.055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
11 Miller MM. Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes. Am J Health Syst Pharm 2017;74:1045-52. [PMID: 28687550 DOI: 10.2146/ajhp60632] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
12 Elberry MH, Darwish NHE, Mousa SA. Hepatitis C virus management: potential impact of nanotechnology. Virol J 2017;14:88. [PMID: 28464951 DOI: 10.1186/s12985-017-0753-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
13 Sepúlveda-Crespo D, Jiménez JL, Gómez R, De La Mata FJ, Majano PL, Muñoz-Fernández MÁ, Gastaminza P. Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture. Nanomedicine 2017;13:49-58. [PMID: 27562210 DOI: 10.1016/j.nano.2016.08.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
14 Abd-Rabou AA, Eskander EF, Mohamed MS, Yahya SMM, Sherbini AE, Shaker OG. P53 rs1042522 and CD95 rs1800682 genetic variations in HCV-4a response to antiviral therapy. Genes Dis 2015;2:197-210. [PMID: 30258864 DOI: 10.1016/j.gendis.2015.02.004] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Sandomenico A, Leonardi A, Berisio R, Sanguigno L, Focà G, Focà A, Ruggiero A, Doti N, Muscariello L, Barone D, Farina C, Owsianka A, Vitagliano L, Patel AH, Ruvo M. Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422. J Virol 2016;90:3745-59. [PMID: 26819303 DOI: 10.1128/JVI.02397-15] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]